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Abstract
Background: The latero-capsular part of the central nucleus of the amygdala (CeLC) is the target
of the spino-parabrachio-amygdaloid pain pathway. Our previous studies showed that CeLC
neurons develop synaptic plasticity and increased neuronal excitability in the kaolin/carrageenan
model of arthritic pain. These pain-related changes involve presynaptic group I metabotropic
glutamate receptors (mGluRs) and postsynaptic NMDA and calcitonin gene-related peptide
(CGRP1) receptors. Here we address the role of group II mGluRs.
Results: Whole-cell current- and voltage-clamp recordings were made from CeLC neurons in
brain slices from control rats and arthritic rats (>6 h postinjection of kaolin/carrageenan into the
knee). Monosynaptic excitatory postsynaptic currents (EPSCs) were evoked by electrical
stimulation of afferents from the pontine parabrachial (PB) area. A selective group II mGluR agonist
(LY354740) decreased the amplitude of EPSCs more potently in CeLC neurons from arthritic rats
(IC50 = 0.59 nM) than in control animals (IC50 = 15.0 nM). The inhibitory effect of LY354740 was
reversed by a group II mGluR antagonist (EGLU) but not a GABAA  receptor antagonist
(bicuculline). LY354740 decreased frequency, but not amplitude, of miniature EPSCs in the
presence of TTX. No significant changes of neuronal excitability measures (membrane slope
conductance and action potential firing rate) were detected.
Conclusion: Our data suggest that group II mGluRs act presynaptically to modulate synaptic
plasticity in the amygdala in a model of arthritic pain.
Background
The amygdala plays a key role in the emotional processing
of sensory stimuli [1-3]. Pain has a strong emotional com-
ponent and is significantly associated with affective disor-
ders such as depression and anxiety [4]. Accumulating
evidence suggests that the amygdala is a neural substrate
of the reciprocal relationship between pain and affect [5].
It has become clear now that lesions and pharmacological
deactivation of the amygdala produce inhibitory effects
on pain behavior in animals [6-8]. Several neuro-imaging
studies have repeatedly identified pain-related signal
changes in the amygdala in animals and humans [8-12].
The amygdala contains several anatomically and physio-
logically distinct nuclei. The central nucleus of the amy-
gdala (CeA) is of particular interest because of its
morphological and functional characteristics. Neurons in
the latero-capsular part of the CeA (CeLC) receive rela-
tively unprocessed nociceptive information directly (not
involving thalamus and/or cortex) through the spino-
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parabrachio-amygdaloid pain pathway arising from lam-
ina I neurons in the spinal cord [5,13,14] Direct spino-
amygdaloid connections from spinal neurons in deeper
laminae may also provide nociceptive information to the
CeA [15]. The CeLC receives highly processed polymodal
information with affective valence from the lateral and
basolateral nuclei of the amygdala, the center of the fear-
anxiety circuitry [16]. The CeA is the major output nucleus
of the amygdala and projects to a variety of "upstream"
and "downstream" targets that are involved in emotional
behavior and emotional experience, autonomic and
somatomotor functions and endogenous pain control
[1,5,13,16,17].
The CeLC is now defined as the "nociceptive amygdala"
because of its high content of nociceptive neurons [5].
Previous in vivo studies showed that the majority of CeLC
neurons, including multireceptive and normally non-
responsive neurons, are sensitized to sensory inputs after
the induction of arthritic pain in one knee [8,18-20]. The
sensitization consists of increased background activity,
stronger activation by constant electrical stimulation of
afferent inputs, and enhanced responses to brief noxious
and innocuous stimulation (compression) of the arthritic
knee and of non-injured tissue. Parallel in vitro whole-cell
patch-clamp recordings in brain slices indicated that syn-
aptic transmission to the CeLC is facilitated in the arthritis
pain model [8,21-23]. Excitability of CeLC neurons is also
enhanced in brain slices from arthritic rats.
The mechanisms of pain-related plasticity in the amygdala
are only beginning to emerge, but glutamate receptors
appear to be of critical importance. Metabotropic gluta-
mate receptors (mGluRs) form a family of G-protein cou-
pled receptors and have been implicated in
neuroplasticity associated with normal brain functions as
well as in a variety of nervous system disorders [24,25]. It
is clear now that mGluRs also play an important role in
nociception and pain [26-30]. Eight mGluR subtypes have
been cloned to date and are classified into groups I
(mGluR1,5), II (mGluR2,3) and III (mGluR4,6,7,8).
Group I mGluRs couple to the activation of phospholi-
pase C, resulting in calcium release from intracellular
stores and protein kinase C (PKC) activation. In contrast,
groups II and III mGluRs are negatively coupled to adeny-
lyl cyclase, thereby inhibiting cyclic AMP (cAMP) forma-
tion and cAMP-dependent protein kinase (PKA)
activation.
Our previous studies showed that arthritis pain-related
sensitization and synaptic plasticity in the CeLC depend
on presynaptic group I mGluR upregulation [19,21] and
on postsynaptic N-methyl-D-aspartate (NMDA) receptor
phosphorylation through the cAMP-dependent protein
kinase PKA [20,22]. PKA activation is accomplished
through postsynaptic calcitonin gene-related (CGRP1)
receptors [8]. Conversely, activation of presynaptic group
III mGluRs inhibited pain-related synaptic plasticity in the
CeLC [23].
Here we analyze the role of group II mGluRs in pain-
related plasticity in the CeLC. The rationale is as follows.
1) Group II mGluRs couple to the inhibition of stimu-
lated cAMP formation, and cAMP-dependent PKA plays
an important role in pain-related plasticity in the CeLC
[5,20,22]. 2) There is evidence to suggest that group II
mGluRs on primary afferents, in the spinal cord and
brainstem modulate nociceptive processing but the role
group II mGluRs in higher brain centers in prolonged or
chronic pain states remains to be determined
[26,27,29,30]. 3) Finally, potential clinical indications for
group II mGluR agonists include anxiety disorders
[24,31], which critically involve the amygdala; the recip-
rocal relationship between pain and anxiety is well docu-
mented [5].
Results
A selective group II mGluR agonist (LY354740) inhibits 
pain-related synaptic plasticity more potently than normal 
synaptic transmission
Our previous studies showed that CeLC neurons undergo
several neuroplastic changes in the kaolin/carrageenan
mono-arthritis pain model [8,21-23]. These changes
include enhanced input-output functions of synaptic
transmission at the PB-CeLC synapse (part of the spino-
parabrachio-amygdaloid pain pathway [see [5]]),
enhanced excitability and altered intrinsic membrane
properties such as resting membrane potential, input
resistance, membrane slope conductance and action
potential threshold. These observations indicate synaptic
and neural plasticity because arthritis pain-related
changes are preserved in the reduced slice preparation and
maintained, at least in part, independently of peripheral
and spinal pain mechanisms [see [5]].
In the present study, monosynaptic excitatory synaptic
currents (EPSCs; see Methods) were recorded in neurons
of the latero-capsular division of the central nucleus of the
amygdala (CeLC) in brain slices from normal rats (n = 9
neurons) and from arthritic rats (6 h postinjection of kao-
lin/carrageenan into the knee; n = 13 neurons). Under
normal conditions, a selective group II mGluR agonist
(LY354740, 1 nM) [24,31] slightly inhibited the peak
amplitude of monosynaptic EPSCs evoked at the PB-CeLC
synapse (see individual example in Fig. 1A). In brain slices
from arthritic rats, the same low concentration of
LY354740 (1 nM) produced stronger inhibition of synap-
tic transmission (see individual example in Fig. 1B). The
inhibitory effects of LY354740 did not involve GABAergic
mechanisms since they were not blocked by bicucullineMolecular Pain 2006, 2:18 http://www.molecularpain.com/content/2/1/18
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(20  µM; Fig. 1C). CeLC neurons in brain slices from
arthritic rats showed significantly increased synaptic
transmission (n = 12, unpaired t-test; Fig. 1D), which is
consistent with our previous studies [8,21-23]. Fig. 1D
shows the significantly increased peak EPSC amplitudes
of neurons in slices from arthritic animals. Our previous
studies determined that this measure reliably reflects
altered input-output function at the PB-CeLC synapse
[8,21-23]. Analysis of the cumulative concentration-
response relationships (Fig. 1E; see Methods) showed a
Increased inhibitory potency of a group II mGluR agonist in the arthritis pain model Figure 1
Increased inhibitory potency of a group II mGluR agonist in the arthritis pain model. A: A selective group II mGluR 
agonist (LY354740; 1 nM, 12 min) has little inhibitory effect in a CeLC neuron recorded in a slice from a normal rat. B: In a 
CeLC neuron from an arthritic rat, LY354740 (1 nM, 12 min) strongly decreases the EPSC amplitude. A, B: Each trace is the 
average of 10 monosynaptic EPSCs evoked at the PB-CeLC synapse and recorded in whole-cell voltage-clamp at -60 mV (see 
Methods). C: LY354740 (1 µM) inhibited synaptic transmission in a CeLC neuron from a normal rat in the presence of bicucul-
line (20 µM) to block GABAA receptors. Bicuculline alone had no apparent effect. D: The mean EPSC amplitude of CeLC neu-
rons from arthritic rats (n = 13) was significantly higher compared to neurons from normal rats (n = 12, unpaired t-test), 
suggesting enhanced synaptic transmission (synaptic plasticity). E: Cumulative concentration-response relationships (see Meth-
ods) show that LY354740 inhibits synaptic transmission in CeLC neurons from arthritic rats more potently than in control 
neurons from normal rats (P < 0.01, F1,45 = 7.89, two way ANOVA). IC50s are 15.0 nM (normal) and 0.59 nM (arthritis). Peak 
amplitudes of EPSCs recorded at the PB-CeLC synapse during each concentration of LY354740 in neurons from normal rats (n 
= 9) and neurons from arthritic rats (n = 13) were averaged and expressed as percent of predrug (baseline) control (100%). 
LY354740 was applied by superfusion of the slice in ACSF for 12 min. Symbols and error bars represent mean ± SE. IC50 values 
were calculated as described in Methods. * P < 0.05.
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25-fold increase in potency of LY354740 in the arthritis
pain model (EC50 = 0.59 nM, n = 13; Fig. 1E, filled circles)
compared to compared t normal conditions (EC50 = 15.0
nM, n = 9; Fig. 1E, open circles). The leftward shift of the
LY354740 concentration-response function functio in the
arthritis pain model was significant (P < 0.01, F1,45 = 7.89,
two way ANOVA). Differences between concentrations
were highly significant (P < 0.0001; F 6,45 = 26.92). Con-
sistent with the parallel shift of the concentration-
response curves, there was no significant interaction (P >
0.05; F 6,45 = 1.01).
A selective group II mGluR antagonist (EGLU) reverses the 
effects of LY354740
A selective group II mGluR antagonist (EGLU, 10 µM)
[25,32] was used to verify receptor-mediated effects of
LY354740 and to determine any intrinsic or endogenous
receptor activation. Fig. 2A shows the time course of the
effects of successive applications of LY354740 and EGLU
coapplied with LY354740 in an individual CeLC neuron
from an arthritic animal. In the sample of CeLC neurons
from arthritic rats (n = 7; Fig. 2B), LY354740 alone (10
nM, 10 min) suppressed the EPSC amplitude to 64.4% ±
4.82 of the predrug value. The inhibitory effect of
LY354740 was significantly attenuated (P < 0.05, paired t-
test, n = 5) by the co-application of LY354740 (10 nM)
and (EGLU; 10 µM, 10–12 min). EGLU alone (10 µM,
10–12 min) had no effect on synaptic transmission in
CeLC neurons from arthritic rats (97.0% ± 4.85 of predrug
control, n = 7; Fig. 2B).
LY354740 acts pre- rather than postsynaptically in the 
CeLC
To determine the site of group II mGluR action in the
CeLC we used a number of well-established electrophysi-
ological methods, including the analysis of amplitude and
frequency of spontaneous miniature EPSCs (mEPSCs)
(Fig. 3), current-voltage relationships (Fig. 4) and neuro-
nal excitability (Fig. 5). These parameters were measured
before and during application of LY354740 in amygdala
brain slices from arthritic rats.
The analysis of spontaneous mEPSCs in the presence of
TTX is a well established electrophysiological approach to
determine pre- versus post-synaptic mechanisms. Presyn-
aptic changes at the transmitter release site affect mEPSC
frequency, whereas changes at the postsynaptic mem-
brane would alter mEPSC amplitude (quantal size)
[8,33]. LY354740 decreased the frequency, but not ampli-
tude, of mEPSCs recorded in TTX (1 µM)-containing ACSF
in slices from arthritic rats (Fig. 3). This presynaptic effect
is illustrated in the current traces recorded in voltage-
clamp mode in an individual CeLC neuron (Fig. 3A). In
the sample of neurons, LY354740 decreased the mean
mEPSC frequency significantly (53.4 ± 12.8% of predrug,
A selective group II mGluR antagonist (EGLU) reverses the  inhibitory effect of LY354740 Figure 2
A selective group II mGluR antagonist (EGLU) 
reverses the inhibitory effect of LY354740. A: Whole-
cell voltage-clamp recordings of an individual CeLC neuron in 
a brain slice from an arthritic rat show that LY354740 (10 
nM) alone decreases the EPSC amplitude. This synaptic inhi-
bition is largely reversed during co-administration of EGLU 
(10 µM). Following washout (>15 min), synaptic strength 
(peak amplitude) returns to baseline. B: EGLU (10 µM, 10–
12 min) has no effect on EPSCs when applied alone (P > 0.05, 
Mann-Whitney U-test, n = 7) but reverses inhibition induced 
by LY354740. In the presence of EGLU (10 µM) the inhibi-
tory effects of LY354740 (10 nM) are significantly attenuated 
(P < 0.05, paired t-test, n = 5). Inhibition of EPSC amplitude 
is expressed as the percentage of predrug controls (mean ± 
SE). * P < 0.05.
0
50
100 *
LY354740 LY354740
+ EGLU
EGLU
 
E
P
S
C
 
(
%
 
c
o
n
t
r
o
l
)
-10 0 10 20 30 40 50 60
60
40
20
control
LY354740
EGLU
wash
time (min)
E
P
S
C
 
a
m
p
l
i
t
u
d
e
 
(
p
A
)
B
A
40 pA
40 msMolecular Pain 2006, 2:18 http://www.molecularpain.com/content/2/1/18
Page 5 of 12
(page number not for citation purposes)
Miniature EPSC (mEPSC) analysis indicates pre- rather than post-synaptic effects of LY354740 Figure 3
Miniature EPSC (mEPSC) analysis indicates pre- rather than post-synaptic effects of LY354740. A: Original cur-
rent traces of mEPSC recorded in an individual CeLC neuron in the presence of TTX (1 µM) show that LY354740 (1 µM) 
reduces frequency but not amplitude of mEPSCs. The CeLC neuron was recorded in a slice from an arthritic rat. B, C: Nor-
malized cumulative distribution analysis of mEPSC amplitude and frequency shows that LY354740 causes a significant shift 
toward higher inter-event intervals (decreased frequency) (B, P < 0.005, maximal difference in cumulative fraction = 0.183, 
Kolmogorov-Smirnov test) but had no effect on the amplitude distribution (C). LY354740 selectively decreased mean mEPSC 
frequency (events/s) (P < 0.05, paired t-test) but not mEPSC amplitude in the sample of neurons (n = 4; see bar histograms in 
B, C). Symbols and error bars represent mean ± SE. Neurons were recorded in voltage-clamp at -60 mV. * P < 0.05.
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Activation of group II mGluRs has no significant effect on current-voltage relationship and membrane slope conductance Figure 4
Activation of group II mGluRs has no significant effect on current-voltage relationship and membrane slope 
conductance. A: Voltage-clamp recordings of whole-cell currents elicited in one CeLC neuron by a series of 400 ms voltage 
steps (-110 to -40 mV) from a holding potential of -60 mV in control ACSF and during application of LY354740 (1 µM, 10 min). 
B: Current-voltage relationship of the same neuron as in A was calculated from the steady state current traces in A. C: Mem-
brane slope conductance (in nS) is calculated from the current-voltage (I-V) relationships constructed from steady-state cur-
rent traces like those shown in A in the presence and absence of the different concentrations of LY354740. In the sample of 
CeLC neurons (n = 13) LY354740 (1–1000 nM) had no significant effect on membrane slope conductance compared to pre-
drug control "0" (P > 0.05, ANOVA with post-hoc Dunnett's test). Symbols and error bars represent mean ± SE. Neurons 
were held at -60 mV.
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LY354740 has no effect on neuronal excitability of CeLC neurons in the arthritis pain model Figure 5
LY354740 has no effect on neuronal excitability of CeLC neurons in the arthritis pain model. A: Current-clamp 
recordings of action potentials (top) generated in a CeLC neuron by direct (through the patch electrode) intracellular injec-
tions of current pulses (500 ms; bottom) of increasing magnitude before and during LY354740 administration. LY354740 (1 
µM, 10 min) did not change action potential firing rate. B: Action potential firing rate measured by intracellular injection of cur-
rent pulses of increasing magnitude (50 pA steps) was not significantly changed in the presence of LY354740 (1 µM) (n = 6). 
Symbols and error bars represent mean ± SE. For the measurement of action potential firing in current clamp, neurons were 
recorded at -60 mV.
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P < 0.05, paired t-test, n = 4; Fig. 3B). LY354740 had no
effect on the amplitude of mEPSCs (103 ± 5.83% of pre-
drug, P > 0.05, paired t-test, n = 4; Fig. 3C). In the absence
of evidence for postsynaptic mechanisms at the concen-
tration of maximal effect (1 µM), it is unlikely that any
postsynaptic effects are caused by lower concentrations, at
which the lower potency o fLY354740 under normal con-
ditions compared to arthritis is revealed.
Concentrations of LY354740 that clearly decreased synap-
tic transmission did not change the membrane slope con-
ductance measured from the current-voltage (I-V)
relationships. Fig. 4A shows steady-state current traces
elicited by a series of voltage steps in an individual CeLC
neuron before (control) and during application of
LY354740 (1 µM). The I-V relationship calculated from
the steady state current traces shown in Fig. 4A did not
change in the presence of LY354740 (1 µM; Fig. 4B). The
data for the sample of neurons (n = 13) are summarized
in Fig. 4C. LY354740 (1 nM – 1 µM) had no significant
effect on the membrane slope conductances measured
from the I-V relationships of individual neurons.
LY354740 had no significant effect on neuronal excitabil-
ity (Fig. 5). Action potentials were evoked in current-
clamp mode by direct intracellular depolarizing current
injections (500 ms) of increasing magnitude through the
patch electrode (Fig. 5A). Input-output functions of neu-
ronal excitability were obtained by averaging the fre-
quency of action potentials evoked at each current
intensity (Fig. 5B). LY354740 (1 µM) had no significant
effect on action potential ("spike") firing rate in neurons
from arthritic rats.
Taken together, the significant reduction of mEPSC fre-
quency, but not amplitude, and the lack of intrinsic mem-
brane property changes in the presence of LY354740
suggest that group II mGluR-mediated inhibition of syn-
aptic transmission occurs through a pre- rather than post-
synaptic mechanism.
Discussion
The present study is the first to show that group II mGluRs
act as modulators to inhibit pain-related synaptic plastic-
ity in the amygdala. The major findings of this study are as
follows: (1) A selective group II mGluR agonist
(LY354740) inhibits normal synaptic transmission in
slices from normal rats and synaptic plasticity in neurons
from arthritic rats. (2) LY354740 is more potent (25-fold)
in CeLC neurons from animals with arthritis compared to
control neurons from normal animals. (3) Antagonist
(EGLU) studies show that the effects of LY354740 are
receptor-mediated, but there is no evidence for intrinsic/
endogenous receptor activation in slices. (4) The inhibi-
tory effects of LY354740 on mEPSC frequency, but not
amplitude, and the lack of effect on membrane properties
suggest a pre- rather than postsynaptic mechanism of
group II mGluR action in the CeLC.
The increased potency of LY354740 in neurons from
arthritic rats could be explained by increased amount of
receptor expression or increased receptor affinity for the
agonist. Since the efficacy (maximum effect) of the ago-
nist was not changed in the arthritis pain model, it is less
likely that enhanced coupling efficiency to G-protein
mediated second-messenger systems is involved. Group II
mGluRs inhibit adenylyl cyclase via Gi/Go proteins, result-
ing in decreased cyclic AMP (cAMP) formation and cAMP-
dependent protein kinase (PKA) activation [25,26,30].
The underlying mechanism of increased group II mGluR
function remains to be determined. Differential changes
of synaptic inhibition by group II mGluRs in the amy-
gdala (including the CeLC) have been shown in other
models of neuroplasticity. Chronic cocaine treatment
abolished the effects of group II mGluR agonists on syn-
aptic transmission while increased potencies of group II
mGluR agonists were observed in the kindling model of
epilepsy [34,35]. Increased inhibition of synaptic trans-
mission in the amygdala by group III mGluRs, which cou-
ple to similar signal transduction pathways as group II
mGluRs, were observed in the arthritis pain model [23],
following chronic cocaine [35] and in the kindling model
of epilepsy [34,35]. These data suggest that group II
mGluR function depends on the type or origin of neuro-
plasticity and is modulated differently than that of group
III mGluRs.
The inhibitory effect of LY354740 was reversed by a selec-
tive and competitive group II mGluR antagonist (EGLU),
confirming that the effects of LY354740 were receptor-
mediated. Although higher agonist potency was observed
in the arthritic pain model, the fact that EGLU itself had
no significant effect on synaptic transmission would argue
against any intrinsic/endogenous activation of these
receptors in vitro. The absence of effects of EGLU on its
own does not seem to be due to insufficient drug concen-
trations at the receptor because EGLU was able to reverse
the inhibitory effect of the exogenously applied agonist
(LY354740). Group II mGluRs show predominantly
extra-synaptic localizations [24,25,36] such that they are
not readily accessible by endogenous glutamate release
from synaptic vesicles. Thus, antagonists would fail to
produce any effects by themselves. Indeed, antagonist
studies have reported a lack of endogenous activation of
group II mGluRs for several brain areas [34,37,38]. Since
the exogenous activation of group II mGluRs by
LY354740 inhibited presynaptic neurotransmitter release
more potently in the arthritic pain model than under nor-
mal conditions, group II mGluR agonists could be usefulMolecular Pain 2006, 2:18 http://www.molecularpain.com/content/2/1/18
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therapeutics for the management of arthritic pain and its
emotional-affective component. Importantly, group II
mGluRs are becoming intriguing drug targets for a variety
of neuropsychiatric disorders, most notably anxiety and
depression, which are intimately linked to pain [24,31].
The present study suggests a presynaptic mechanism of
group II mGluR effects at the PB-CeLC synapse. Evidence
for a presynaptic site also comes from in situ hybridiza-
tion data showing a relatively high expression of group II
mRNA in the parabrachial nucleus (origin of the PB-CeLC
afferents) but not in the central nucleus [39,40]. Presyn-
aptic inhibition by group II mGluRs has been observed in
several different brain regions including synapses in the
basolateral and central nuclei of the amygdala [34,35],
substantia nigra pars compacta [41], hippocampal areas
[42,43] and corticostriatal synapses [44].
Group II mGluRs have been implicated in nociceptive
processing at different levels of the pain neuraxis, but their
roles are less well understood than those of group I
mGluRs. Activation of group II mGluRs in peripheral tis-
sues had antinociceptive effects in models of inflamma-
tory [27,45,46] and neuropathic pain [47]. Conversely,
blockade of peripheral group II mGluRs (LY341495) pro-
longed PGE2- and carrageenan-induced mechanical allo-
dynia, suggesting that peripheral group II mGluRs
mediate endogenous anti-allodynic effects [46]. Similarly,
peripheral injection of a group II/III antagonist [MSOPPE,
(RS)-alpha-methylserine-O-phosphate monophenyl
ester] enhanced glutamate-induced mechanical allodynia
[27]. Activation of spinal group II mGluRs inhibited
behavior [48,49] and central sensitization [50,51] related
to inflammatory pain. Intracisternal and systemic, but not
intrathecal, administration of group II agonists inhibited
formalin-induced pain behavior [52,53]. Behavioral data
suggest that group II mGluRs in the periaqueductal gray
(PAG) inhibit descending facilitation of pain behavior
thus activating descending pain inhibition [54]. Activa-
tion of group II in the ventrobasal thalamus resulted in
the disinhibition of nociceptive processing through the
presynaptic reduction of GABAergic inhibition [55].
Methods
Male Sprague Dawley rats (90 g–190 g; mean 130 g) were
housed in a temperature controlled room and maintained
on a 12 h day/night cycle. Water and food were available
ad libitum. Electrophysiological data were obtained from
untreated normal rats and rats with monoarthritis in the
knee (6 h after induction). All experimental procedures
were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Texas Medical
Branch (UTMB) and conform to the guidelines of the
International Association for the Study of Pain (IASP) and
of the National Institutes of Health (NIH).
Arthritis pain model
In the group of arthritic rats, arthritis was induced in the
left knee joint as previously described [8,19-21]. A kaolin
suspension (4%, 100 µl) was injected into the left knee
joint cavity through the patellar ligament. After repetitive
flexions and extensions of the knee for 15 minutes, a car-
rageenan solution (2%, 100 µl) was injected into the knee
joint cavity, and the leg was flexed and extended for
another 5 minutes. Brain slices for the electrophysiologi-
cal studies were obtained 6 hours after arthritis induction.
Amygdala slice preparation
After decapitation, the brains were quickly dissected out
and blocked in cold (4°C) artificial cerebrospinal fluid
(ACSF) containing (in mM) 117 NaCl, 4.7 KCl, 1.2
NaH2PO4, 2.5 CaCl2, 1.2 MgCl2, 25 NaHCO3, and 11 glu-
cose. ACSF was oxygenated and equilibrated to pH7.4
with a mixture of 95% O2 and 5% CO2. Coronal brain
slices (500 µm) containing the CeLC were prepared using
a Vibroslice (Camden instruments, London, UK). The
slices were then incubated in ACSF at room temperature
(21°C) for at least 1 h and a single brain slice was trans-
ferred to the recording chamber and submerged in ACSF
(31 ± 1°C), which superfused the slice at ~2 ml/min.
Whole-cell patch-clamp recording
Whole-cell patch-clamp recordings using the "blind"
patch technique were obtained from CeLC neurons as
described before [8,13,21,22]. Patch electrodes were
made from 1.5 mm borosilicate glass capillaries (1.5 mm
outer diameter, 1.12 mm inner diameter; Drummond,
Broomall, PA) pulled on a Flaming-Brown micropipette
puller (P-80/PC; Sutter Instrument Co., Novato, CA).
Recording electrodes were positioned in the CeLC under
visual control. The boundaries of the CeLC are easily dis-
cerned under light microscopy (see Fig. 8A in [8]); each
slice was matched with the corresponding level in Paxinos
and Watson (1998). The internal solution of the recording
electrodes (4- to 6-MΩ tip resistance) contained (in mM)
122 K-gluconate, 5 NaCl, 0.3 CaCl2, 2 MgCl2, 1 EGTA, 10
HEPES, 5 Na2-ATP, and 0.4 Na3-GTP; pH was adjusted to
7.2–7.3 with KOH and the osmolarity to 280 mmol/kg
with sucrose.
After tight (>1GΩ) seals were formed and the whole-cell
configuration was obtained, neurons were included in the
sample if the resting membrane potential was more nega-
tive than -50 mV and action potentials overshooting 0 mV
were evoked by direct cathodal stimulation. Voltage and
current signals were low-pass filtered at 1 kHz with a dual
4-pole Bessel filter (Warner Instrument Corp., Hamden,
CT), digitized at 5 KHz (Digidata 1322 interface, Axon
Instruments, Foster City, CA), and stored on a Pentium 4
computer (Dell). Data were also continuously recorded
on a pen chart recorder (Gould 3400, Gould Instr., ValleyMolecular Pain 2006, 2:18 http://www.molecularpain.com/content/2/1/18
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View, OH). Evoked potential and evoked current data
were acquired and analyzed using pCLAMP8 software
(Axon Instruments, Foster City, CA). Discontinuous sin-
gle-electrode voltage clamp (d-SEVC) recordings were
acquired using an Axoclamp-2B amplifier (Axon Instru-
ments) with a switching frequency of 5–6 kHz (30% duty
cycle), gain of 3–8 nA/mV, and time constant of 20 ms.
Phase shift and anti-alias filter were optimized. The head-
stage voltage was monitored continuously on a digital
oscilloscope (Gould 400, Gould Instr., Modesto, CA) to
ensure precise performance of the amplifier. Neurons
were held at -60 mV.
Synaptic stimulation
We studied transmission at the parabrachial area (PB)-
CeLC synapse that provides nociceptive input to the CeLC
from the spinal cord and brainstem (see Introduction).
Using a concentric bipolar stimulating electrode (Kopf
Instruments) of 22 kΩ resistance, excitatory postsynaptic
currents (EPSCs) were evoked in CeA neurons by electrical
stimulation (using a Grass S88 stimulator, Grass Instr.) of
the PB-CeLC synapse. The stimulation electrode was posi-
tioned under microscopic control on the fibers dorsome-
dial to the CeA and ventral to but outside of the caudate-
putamen [8,21,22] (see Fig. 8A in [8]). Electrical stimuli
(150 µs square-wave pulses) were delivered at frequencies
below 0.25 Hz. Input-output relations were obtained by
increasing the stimulus intensity in 100 µA steps. For eval-
uation of a drug effect on synaptically evoked responses,
the stimulus intensity was adjusted to 80% of the intensity
required for orthodromic spike generation, which was on
average 350–450 µA.
Drugs
The following drugs were used: (S)-alpha-ethylglutamic
acid (EGLU; selective group II mGluR antagonist [25,32],
purchased from Tocris Cookson Inc., Ellisville, MO; (+)-2-
aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
(LY354740; selective group II mGluR agonist [24,31], a
generous gift from Eli Lilly and Company. All drugs were
dissolved in ACSF and applied by gravity-driven super-
fusion of the slice in ACSF. Solution flow into the record-
ing chamber (1 ml volume) was controlled with a three-
way stopcock. Drug applications were for at least 10 min
in duration to establish equilibrium in the tissue.
Data analysis and statistics
All averaged values are given as the mean ± SE. Statistical
significance was accepted at the level of P < 0.05. Concen-
tration-response relationships were compared using a
two-way analysis of variance (ANOVA). IC50 values were
calculated from sigmoid curves fitted to the cumulative
concentration-response data by nonlinear regression
using the formula y = A + (B - A)/[1 + (10C/10X)D], where
A = bottom plateau, B = top plateau, C = log(IC50), D =
slope coefficient (GraphPad Prism 3.0). Using the linear
curve fit function of pClamp software (Axon Instru-
ments), membrane slope conductances (in nS) in the
absence and presence of agonists were calculated from the
linear portion of the current-voltage (I-V) relationships
recorded in voltage-clamp mode. An ANOVA with post-
hoc Dunnett's test was used to compare the drug effects on
membrane slope conductance to the predrug control
value. Drug effects (agonist and antagonist) were com-
pared to predrug control values using the paired t-test.
mEPSCs were analyzed for frequency and amplitude dis-
tributions using the MiniAnalysis program 5.3 (Synap-
tosoft Inc., Decatur, GA). The detection threshold was set
to 3 times the average RMS noise level during event-free
sections (typically 10 pA; see Fig. 3C). The analysis was re-
checked manually. The Kolmogorov-Smirnov test was
used for the cumulative distribution analysis of mEPSC
amplitude and frequency while the paired t-test compared
mean amplitude and frequency of mEPSCs.
Conclusion
Activation of presynaptic group II mGluRs in the CeLC
inhibits synaptic plasticity in a model of arthritis pain
more potently than normal synaptic transmission, sug-
gesting that presynaptic group II mGluRs in the CeLC may
be potential therapeutic targets for pain relief.
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